Koa Wealth Management LLC Makes New Investment in Perspective Therapeutics, Inc. (NYSE:CATX)

Koa Wealth Management LLC acquired a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 25,975 shares of the company’s stock, valued at approximately $83,000.

Several other large investors also recently modified their holdings of CATX. FMR LLC boosted its holdings in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Nicholson Wealth Management Group LLC bought a new position in Perspective Therapeutics during the third quarter worth $21,390,000. State Street Corp grew its holdings in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Hills Bank & Trust Co bought a new stake in Perspective Therapeutics in the third quarter valued at $13,722,000. Finally, Janus Henderson Group PLC raised its holdings in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares during the period. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CATX has been the subject of several research reports. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Friday, January 24th. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $24.00 to $5.00 in a report on Monday, November 25th. Oppenheimer cut their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. UBS Group assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.14.

Insider Activity

In other news, Director Heidi Henson acquired 25,975 shares of Perspective Therapeutics stock in a transaction on Wednesday, December 4th. The stock was acquired at an average cost of $3.85 per share, with a total value of $100,003.75. Following the completion of the acquisition, the director now owns 25,975 shares in the company, valued at approximately $100,003.75. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Johan M. Spoor bought 14,500 shares of the stock in a transaction on Monday, November 25th. The stock was purchased at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the purchase, the chief executive officer now owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. This trade represents a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 67,570 shares of company stock valued at $256,789 in the last ninety days. 3.52% of the stock is currently owned by insiders.

Perspective Therapeutics Price Performance

CATX opened at $3.81 on Friday. Perspective Therapeutics, Inc. has a fifty-two week low of $2.70 and a fifty-two week high of $19.05. The company’s 50-day moving average is $3.51 and its 200 day moving average is $9.57.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.